Clinical AI has entered its operations phase. After years of pilot proliferation, health systems are consolidating around a smaller set of trustworthy tools that fit existing radiology and cardiovascular workflows. United Imaging’s preference for a non-extreme rollout signals where the market has moved: from feature sprints to production readiness. Buyers want prospective validation on representative cohorts, predictable latency on commodity GPUs, clean PACS/RIS hooks, and fail-safe behavior when data quality degrades. Vendors who optimize for deployment quality are gaining approvals from clinical leadership and biomedical engineering alike, while hype-led portfolios struggle to survive change-control boards and safety committees.
The constraint is no longer model novelty; it’s system reliability and operator trust. Radiologists will not tolerate tools that add mouse-miles, fragment hanging protocols, or flood them with low-value flags. CIOs will not greenlight sprawling agent fleets that complicate cybersecurity, data governance, and vendor management. What carries the buying committee is a narrow promise delivered flawlessly: better triage times, fewer repeat scans, cleaner reports, or tighter throughput on high-demand modalities. That requires robust MLOps, post-market surveillance, escalation paths, and a clear operating envelope disclosed to clinicians, not just accuracy headlines from retrospective test sets.
For decision-makers, the evaluation lens should look like a safety-critical software purchase, not a research trial. Demand prospective or external validation on similar scanners and patient mix; verify DICOM handling for edge cases; require SSO, audit logs, and RBAC; and test degradation gracefully under network jitter. Contracts should tie payments to operating KPIs—turnaround time, flagged-case precision at clinically acceptable recall, downtime caps, and integration milestones. Finally, plan change management: short, modality-specific training; clear feedback channels to vendors; and governance that kills underperforming models quickly. In clinical AI, fewer tools done well beats maximal installation every time.